MedCity Pivot Podcast: A Conversation With AliveCor’s Priya Abani
In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies.
In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies.
A new class action lawsuit accuses Oura of overstating its smart ring's sleep tracking accuracy, arguing the device relies on AI-generated estimates rather than the clinical measurements needed for true sleep staging. The case is reigniting questions about how much precision consumers should expect from AI-powered health wearables.
Verily and Samsung are partnering to integrate data from Galaxy smartwatches into Verily’s Pre platform. The goal is to create an end-to-end system that pharma researchers can use to deploy wearable devices in studies, analyze patient data remotely and then interpret the results.
French startup Naox Technologies this month became the first company to receive FDA 510(k) clearance for an in-ear EEG device. The system seeks to improve care for neurological conditions like epilepsy, Alzheimer’s and sleep disorders by capturing brain activity in everyday settings that traditional scalp-based EEGs often miss.
Picture each patient with a computational model of their health where each treatable parameter (like weight, blood pressure, heart rate, exercise, inflammation, and blood chemistry) serves both as a marker for diagnosis and as an opportunity for treatment.
Sibel Health raised $30 million to accelerate the commercial deployment of its remote patient monitoring platform. The company also announced its seventh FDA clearance, which enables clinicians to use alarms and alerts along with the Sibel’s central platform.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Fidelity Management & Research Company and Dexcom participated in ŌURA’s $200 million Series D round.
MIT spinout Bloomer Tech is developing a wearable electrocardiogram device designed to look and feel like a bra.
Wearable technology seems to offer great potential for early detection and management of agitation experienced by people with communication-impaired neurological disorders, allowing caregivers to provide personalized interventions that could significantly improve patients’ lives.
ŌURA announced two new heart health features on Friday: one that estimates cardiovascular age and one that measures cardio capacity.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications. But the startup envisions its technology eventually also finding a place as a part of clinical care.
Biolinq raked in $58 million in capital this week. The company is developing a wearable patch that uses electrochemical sensors to measure a person’s glucose levels from the intradermal space just beneath the surface of their skin.
Oura — a company selling a ring that tracks peoples’ biometrics — announced new partnerships with three providers of continuous glucose monitors: January, Supersapiens and Veri. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users’ glucose levels and overall health.
Wearables company Movano Health recently partnered with Novant Health to beta test its smart ring — which is designed for women — with the health system’s employees. The program is expected to prepare Movano for its first direct-to-consumer product launch in the first half of next year.
Cala Health recently published a post-market study showing that its wrist-based wearable to treat essential tremor effectively reduced patients' tremor power with no loss of effect over time. Most patients involved in the study reported improvement in daily activities, such as eating, drinking, texting and writing.